Evaluation of treatment for gastro-oesophageal reflux disease with a proton pump inhibitor, and relationship between gastro-oesophageal reflux disease and Helicobacter pylori infection in Japan

Aliment Pharmacol Ther. 2004 Jul:20 Suppl 1:102-6. doi: 10.1111/j.1365-2036.2004.01983.x.

Abstract

Background: Effective therapy for gastro-oesophageal reflux disease (GERD) is associated with improvement in health-related quality of life. It remains unclear whether Helicobacter pylori infection protects against GERD.

Aim: We evaluated the relationship between GERD and H. pylori, and whether the health-related quality of life score improved after medical treatment.

Methods: We enrolled 151 outpatients with upper abdominal symptoms; 81 patients received omeprazole 20 mg/day for 2 weeks. Health-related quality of life was assessed using the Gastrointestinal Symptom Rating Scale (GSRS) and the Psychological General Well-Being (PGWB) index. H. pylori infection was diagnosed by serum antibody or endoscopy and the relationship between GERD and H. pylori was evaluated.

Results: In GERD patients, the mean GSRS score improved from 2.20 to 1.67 following treatment (P < 0.01). The mean GSRS reflux symptom score improved from 2.96 to 1.67 (P < 0.01). The mean PGWB score improved from 96.36 to 107.34 (P < 0.01). All scores in GERD patients significantly improved compared with non-GERD patients. The H. pylori-positive ratio was 66.15% in GERD patients and 65.21% in non-GERD patients (P = 0.94).

Conclusions: Health-related quality of life is useful for evaluation of proton pump inhibitor treatment in GERD. The presence of H. pylori was not associated with the prevalence of GERD.

MeSH terms

  • Anti-Ulcer Agents / therapeutic use*
  • Female
  • Gastroesophageal Reflux / drug therapy*
  • Gastroesophageal Reflux / microbiology
  • Helicobacter Infections / complications
  • Helicobacter Infections / drug therapy*
  • Helicobacter pylori*
  • Humans
  • Male
  • Middle Aged
  • Omeprazole / therapeutic use*
  • Proton Pump Inhibitors*
  • Quality of Life
  • Surveys and Questionnaires
  • Treatment Outcome

Substances

  • Anti-Ulcer Agents
  • Proton Pump Inhibitors
  • Omeprazole